NCT06422689 - Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care | Biotech Hunter

Enrollment

1,500

Participants

Timeline

Start Date

May 10, 2024

Primary Completion Date

April 29, 2026

Study Completion Date

April 29, 2026

Conditions

Asthma

Interventions

DRUG

Albuterol and budesonide inhalation aerosol

Participants will receive a fixed-dose combination of albuterol (90mcg) and budesonide (80mcg) administered as 2 inhalations (180mcg/160mcg) via pressurized metered dose inhaler (pMDI) as needed for asthma symptoms, for up to 12 inhalations (6 doses) in a 24-hour period.

Trial Locations (12)

15801

RECRUITING

Research Site, DuBois

27834

RECRUITING

Research Site, Greenville

28803

RECRUITING

Research Site, Asheville

40217

RECRUITING

Research Site, Louisville

48109

RECRUITING

Research Site, Ann Arbor

48532

RECRUITING

Research Site, Flint

55425

RECRUITING

Research Site, Minneapolis

78738

TERMINATED

Research Site, Austin

91602

RECRUITING

Research Site, North Hollywood

94598

RECRUITING

Research Site, Walnut Creek

02111

RECRUITING

Research Site, Boston

01199

WITHDRAWN

Research Site, Springfield